Donath et al. discussed the rationale and effect of some of anti-inflammatory treatments in patients with diabetes, including IL-1 receptor blockade, IL-1β antagonism, and TNF antagonism, which showed protective effects in T2D 50. Here, IL1B is linked to type 2 diabetes mellitus.